Top Ten most popular articles on Pharmafile.com this week

pharmafile | July 21, 2017 | News story | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AstraZeneca, Teva, biotech, brexit, drugs, healthcare, pharma, pharmaceutical, psoriasis, top ten 

The week was characterised by two big psoriasis approval stories, while Amgen’s osteoporosis treatment was knocked back. Novartis CEO Joe Jimenez’s comments regarding the 2018 outlook for the company were of strong consequence to many readers in the industry, while Merck’s restructure announcement was less positive, promising the layoff of 200 employees.

But the headlines were dominated this week by the shock news that AstraZeneca CEO Pascal Soirot would be leaving the company for Teva – news which was later proved to be only speculation.

Check out the week’s ten most popular articles on Pharmafile.com now!

10. J&J uses FDA Priority Review Voucher to snag psoriasis approval

Janssen was granted approval for its treatment of moderate-to-severe psoriasis, after the company used its Priority Review Voucher to speed up approval of the drug.

9. Leo Pharma gets European approval for unique plaque psoriasis drug

The European Commission has announced that it has decided to approve Leo Pharma’s Kyntheum (brodalumab), making it the first and only available therapy to target the IL-17 receptor in the treatment of moderate-to-severe plaque psoriasis in candidates for systemic therapy.

8. Cuba begins Phase 1 testing of HIV vaccine

Cuba once again leads the way with HIV treatment by beginning a trial on a vaccine that would reduce the levels of the virus in the blood without toxic side-effects.

7. FDA refuses approval of Amgen osteoporosis drug

Amgen and its development partner UCB have announced that the FDA has refused to approve Evenity for use in postmenopausal female patients.

6. Merck to lay off 200 as part of 5-year reorganisation plan

German drug manufacturer Merck has announced its intention to streamline its manufacturing processes across Europe as part of a five-year reorganisation programme with a goal of accelerating its production response time to meet customer demand.

5. AstraZeneca’s CEO set for shock switch to Teva

Teva have swooped for Pascal Soriot, of AstraZeneca, to fill the vacancy in its CEO position in a move that has taken many by surprise.

4. Novartis CEO reasserts 2018 growth expectations, discusses Alcon and Sandoz future

Novartis has reiterated its expectation of sales growth beginning in 2018, as well as a positive outlook for its Alcon eye care business, according to Chief Executive Joe Jimenez.

3. Teva accuses ex-employee of passing company secrets to boyfriend at rival generics firm

Teva has launched a lawsuit against Barinder Sandhu, its ex-Chief of Regulatory Affairs, who is accused of passing on trade secrets to her boyfriend Jeremy Desai, the CEO of a rival generics firm.

2. What pharma should know about the European Unitary Patent in light of Brexit

The departure of the United Kingdom from the European Union, dubbed “Brexit,” has sparked significant economic global uncertainty, with two Brexit-related issues especially relevant to the pharmaceutical industry…

1. AstraZeneca’s Soriot Teva switch scotched

AstraZeneca has finally released news to clarify that Soriot will be around in a few weeks’ time to discuss the release of its financial results, effectively kyboshing the speculation.

Related Content


AstraZeneca launches health-tech business, Evinova

AstraZeneca has announced that it has launched Evinova, its new health-tech business, which it is …

FDA approves AstraZeneca’s Truqap plus Faslodex for breast cancer treatment

AstraZeneca has announced that the US Food and Drug Administration (FDA) has approved Truqap (capivasertib) …

AstraZeneca’s Imfinzi meets primary endpoint for liver cancer treatment

AstraZeneca has announced positive results from the EMERALD-1 phase 3 trial for Imfinzi (durvalumab) in …

Latest content